

Maureen M O'brien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6728245/publications.pdf>

Version: 2024-02-01

60
papers

2,107
citations

331670

21
h-index

243625

44
g-index

71
all docs

71
docs citations

71
times ranked

2946
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4381-4389.	1.6	478
2	Second Malignant Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low-Dose Radiation and Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1232-1239.	1.6	160
3	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 884-892.	7.2	158
4	Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Targeted Therapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1113-1115.	1.5	138
5	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. <i>Oncologist</i> , 2018, 23, 52-61.	3.7	123
6	Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2016, 30, 737-749.	16.8	95
7	Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 80.	6.2	68
8	Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 186, 274-285.	2.5	65
9	Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia. <i>Blood</i> , 2016, 128, 2780-2780.	1.4	62
10	Cardiomyopathy in Children With Down Syndrome Treated for Acute Myeloid Leukemia: A Report From the Children's Oncology Group Study POG 9421. <i>Journal of Clinical Oncology</i> , 2008, 26, 414-420.	1.6	59
11	Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. <i>Pediatric Blood and Cancer</i> , 2008, 50, 381-383.	1.5	49
12	A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma. <i>Blood</i> , 2015, 126, 1328-1328.	1.4	43
13	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. <i>Journal of Clinical Oncology</i> , 2022, 40, 956-967.	1.6	42
14	Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML. <i>Blood</i> , 2010, 116, 1070-1070.	1.4	41
15	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. <i>Blood</i> , 2019, 134, 741-741.	1.4	36
16	Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e280-e285.	2.0	35
17	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. <i>Haematologica</i> , 2014, 99, 299-307.	3.5	34
18	Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27400.	1.5	31

#	ARTICLE	IF	CITATIONS
19	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. <i>Blood Cancer Discovery</i> , 2022, 3, 103-115.	5.0	31
20	Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. <i>Blood</i> , 2014, 124, 963-963.	1.4	29
21	Phase I study of valsopodar (PSCâ€833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2010, 54, 694-702.	1.5	26
22	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27618.	1.5	24
23	Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26538.	1.5	22
24	Experience with ponatinib in paediatric patients with leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 363-368.	2.5	21
25	Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a twoâ€site retrospective cohort study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27613.	1.5	20
26	A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 70-70.	1.4	20
27	Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3703-3703.	1.4	19
28	Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment. <i>Blood</i> , 2014, 124, 2292-2292.	1.4	17
29	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. <i>Blood</i> , 2021, 138, 2337-2346.	1.4	16
30	Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e132-e143.	3.8	15
31	Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 128, 209-214.	4.0	13
32	Reducing acute kidney injury in pediatric oncology patients: An improvement project targeting nephrotoxic medications. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28396.	1.5	12
33	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. <i>Blood</i> , 2019, 134, 2649-2649.	1.4	12
34	Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease. <i>Seminars in Hematology</i> , 2020, 57, 157-163.	3.4	11
35	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. <i>Blood</i> , 2015, 126, 3792-3792.	1.4	11
36	Viral surveillance using PCR during treatment of AML and ALL. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26752.	1.5	9

#	ARTICLE	IF	CITATIONS
37	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. <i>Blood</i> , 2020, 136, 37-38.	1.4	8
38	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3873-3873.	1.4	7
39	Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation. <i>Journal of Pediatric Psychology</i> , 2018, 43, 758-768.	2.1	6
40	Radiation dose reduction through combining positron emission tomography/computed tomography (PET/CT) and diagnostic CT in children and young adults with lymphoma. <i>Pediatric Radiology</i> , 2018, 48, 196-203.	2.0	5
41	Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29126.	1.5	5
42	CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. <i>Blood Advances</i> , 2023, 7, 251-255.	5.2	4
43	How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S8-S11.	0.4	3
44	Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28946.	1.5	3
45	Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3824-3824.	1.4	3
46	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. <i>Blood</i> , 2021, 138, 3398-3398.	1.4	3
47	Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27719.	1.5	2
48	Thiopurines for the Treatment of Acute Lymphoblastic Leukemia in Children. <i>JAMA Oncology</i> , 2015, 1, 281.	7.1	1
49	Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation. <i>Pediatric Blood and Cancer</i> , 2016, 63, 551-553.	1.5	1
50	Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 395-408.	0.8	1
51	V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia. <i>Blood</i> , 2019, 134, 3830-3830.	1.4	1
52	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 1235-1235.	1.4	1
53	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 614-614.	1.4	1
54	Defining the Optimal Treatment of First Relapse of Pediatric Relapsed Anaplastic Large-Cell Lymphoma: Clinical Trial Challenges for Rare Diagnoses. <i>Journal of Clinical Oncology</i> , 2020, 38, 3980-3982.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Myeloid Leukemia of Down Syndrome: The Results of An International Retrospective Study. Blood, 2010, 116, 2718-2718.	1.4	0
56	Genomic Characterization Of Histiocytic Lesions Following Pediatric T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 4940-4940.	1.4	0
57	Lymphoid Lineage Preference of MLL-AF4 Is Revealed in a Species-Specific Model. Blood, 2015, 126, 2454-2454.	1.4	0
58	A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia. Blood, 2018, 132, 336-336.	1.4	0
59	Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 4403-4403.	1.4	0
60	Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1970-1970.	1.4	0